Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In September 2010 the EMA decided to suspend the market authorisation of rosiglitazone while the FDA decided to restrict its use. These actions were taken because rosiglitazone had been associated with an increased risk of ischemic heart disease. Remarkably, in 2007, when the evidence against the combination of rosiglitazone and insulin had increased, the EMA made a decision that encouraged the use of insulin in combination with rosiglitazone, while the FDA tried to restrict this combination therapy. Despite the publication of several studies, including a large randomized controlled study, the cardiovascular risk of rosiglitazone has still not been definitively established. To prevent new cases like rosiglitazone, more attention should be given to evaluation of study protocols of safety trials prior to their start. The rosiglitazone story further underlines the critical importance of publicly available trial data.

Type

Journal article

Journal

Pharmaceutisch Weekblad

Publication Date

07/06/2013

Volume

148

Pages

74 - 77